- Home
- Mea Pterygium Drug Market
MEA Pterygium Drug Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-390 | No of pages: 197 | Format:
The Middle East and Africa pterygium drug market are projected to register a substantial CAGR of 3.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Middle East and Africa Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait and Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Middle East and Africa pterygium drug market are:
Increase in healthcare awareness to reduce the risk of eye illnesses
Rising geriatric population
Market Players:
Some of the major players operating in the Middle East and Africa pterygium drug market are:
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Spectra Vision Care
Bayer AG
Zydus Group
Alcon
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET 37
1.4 CURRENCY AND PRICING 39
1.5 LIMITATIONS 39
1.6 MARKETS COVERED 39
2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 DBMR TRIPOD DATA VALIDATION MODEL 46
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
2.6 MULTIVARIATE MODELLING 50
2.7 CLASS SEGMENT LIFELINE CURVE 50
2.8 DBMR MARKET POSITION GRID 51
2.9 VENDOR SHARE ANALYSIS 52
2.10 MARKET END USER COVERAGE GRID 53
2.11 SECONDARY SOURCES 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 59
4.1 PESTEL'S MODEL 60
4.2 PORTER'S 5 FORCES 61
4.3 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES 62
5 EPIDEMIOLOGY 63
6 PIPELINE ANALYSIS 64
7 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: REGULATIONS 65
7.1 REGULATION IN THE U.S. 65
7.2 REGULATION IN EUROPE: 66
7.3 REGULATIONS IN CHINA: 66
7.4 REGULATIONS IN INDIA: 67
7.5 RELEVANT ACTS FOR THIS FRAMEWORK: 67
8 MARKET OVERVIEW 68
8.1 DRIVERS 70
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS 70
8.1.2 RISE IN GERIATRIC POPULATION 70
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES 71
8.2 RESTRAINTS 72
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION 72
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS 72
8.3 OPPORTUNITIES 73
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES 73
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 73
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 74
8.4 CHALLENGES 75
8.4.1 STRINGENT RULES & REGULATIONS 75
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS 76
9 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE 77
9.1 OVERVIEW 78
9.2 PROGRESSIVE PTERYGIUM 81
9.3 ATROPHIC PTERYGIUM 81
10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY STAGES 83
10.1 OVERVIEW 84
10.2 STAGE 2 87
10.3 STAGE 3 87
10.4 STAGE 1 88
10.5 STAGE 4 89
11 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT 90
11.1 OVERVIEW 91
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 94
11.2.1 DEMULCENT 95
11.2.2 EMOLLIENTS 95
11.3 STEROID EYE DROPS 95
11.3.1 KETONE STEROIDS 96
11.3.1.1 PREDNOSOLONE 97
11.3.1.2 DEXAMETHASONE 97
11.3.1.3 FLUROMETHOLONE 97
11.3.1.4 OTHERS 97
11.3.2 ESTER STEROID (LOTERPREDNOL) 97
12 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION 98
12.1 OVERVIEW 99
12.2 EYE DROPS 102
12.2.1 EYE DROPS WITH PRESERVATIVES 102
12.2.2 PRESERVATIVE-FREE EYE DROPS 102
12.3 EYE OINTMENTS 103
12.4 OTHERS 103
13 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE 105
13.1 OVERVIEW 106
13.2 PRESCRIPTION 109
13.3 OVER THE COUNTER (OTC) 109
14 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE 111
14.1 OVERVIEW 112
14.2 GERIATRIC 115
14.3 ADULTS 115
15 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY END USER 117
15.1 OVERVIEW 118
15.2 HOSPITALS 121
15.3 SPECIALTY CLINICS 121
15.4 HOME HEALTHCARE 122
15.5 OTHERS 122
16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL 124
16.1 OVERVIEW 125
16.2 RETAIL PHARMACIES 128
16.3 HOSPITAL PHARMACIES 128
16.4 ONLINE PHARMACIES 129
16.5 OTHERS 129
17 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY REGION 131
17.1 MIDDLE EAST AND AFRICA 132
17.1.1 SOUTH AFRICA 142
17.1.2 EGYPT 145
17.1.3 ISRAEL 148
17.1.4 UAE 151
17.1.5 SAUDI ARABIA 154
17.1.6 KUWAIT 157
17.1.7 REST OF MIDDLE EAST AND AFRICA 160
18 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE 161
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 161
19 SWOT ANALYSIS 162
20 COMPANY PROFILES 163
20.1 ALCON 163
20.1.1 COMPANY SNAPSHOT 163
20.1.2 RECENT FINANCIALS 163
20.1.3 COMPANY SHARE ANALYSIS 164
20.1.4 PRODUCT PORTFOLIO 164
20.1.5 RECENT DEVELOPMENTS 165
20.2 ABBVIE INC. 166
20.2.1 COMPANY SNAPSHOT 166
20.2.2 REVENUE ANALYSIS 166
20.2.3 COMPANY SHARE ANALYSIS 167
20.2.4 PRODUCT PORTFOLIO 167
20.2.5 RECENT DEVELOPMENT 167
20.3 BAUSCH & LOMB INCORPORATED 168
20.3.1 COMPANY SNAPSHOT 168
20.3.2 REVENUE ANALYSIS 168
20.3.3 COMPANY SHARE ANALYSIS 169
20.3.4 PRODUCT PORTFOLIO 169
20.3.5 RECENT DEVELOPMENT 169
20.4 JOHNSON & JOHNSON SERVICES, INC. 170
20.4.1 COMPANY SNAPSHOT 170
20.4.2 REVENUE ANALYSIS 170
20.4.3 COMPANY SHARE ANALYSIS 171
20.4.4 PRODUCT PORTFOLIO 171
20.4.5 RECENT DEVELOPMENTS 171
20.5 BAYER AG 172
20.5.1 COMPANY SNAPSHOT 172
20.5.2 REVENUE ANALYSIS 172
20.5.3 COMPANY SHARE ANALYSIS 173
20.5.4 PRODUCT PORTFOLIO 173
20.5.5 RECENT DEVELOPMENTS 173
20.6 NOVARTIS AG 174
20.6.1 COMPANY SNAPSHOT 174
20.6.2 REVENUE ANALYSIS 174
20.6.3 PRODUCT PORTFOLIO 175
20.6.4 RECENT DEVELOPMENTS 175
20.7 SANTEN PHARMACEUTICAL CO., LTD. 176
20.7.1 COMPANY SNAPSHOT 176
20.7.2 RECENT FINANCIALS 176
20.7.3 PRODUCT PORTFOLIO 177
20.7.4 RECENT DEVELOPMENT 177
20.8 AKORN OPERATING COMPANY LLC 178
20.8.1 COMPANY SNAPSHOT 178
20.8.2 PRODUCT PORTFOLIO 178
20.8.3 RECENT DEVELOPMENT 178
20.9 AMNEAL PHARMACEUTICALS LLC. 179
20.9.1 COMPANY SNAPSHOT 179
20.9.2 REVENUE ANALYSIS 179
20.9.3 PRODUCT PORTFOLIO 180
20.9.4 RECENT DEVELOPMENTS 180
20.10 EYERIS VISIONCARE PVT. LTD. 181
20.10.1 COMPANY SNAPSHOT 181
20.10.2 PRODUCT PORTFOLIO 181
20.10.3 RECENT DEVELOPMENTS 181
20.11 MAYA BIOTECH PRIVATE LIMITED 182
20.11.1 COMPANY SNAPSHOT 182
20.11.2 PRODUCT PORTFOLIO 182
20.11.3 RECENT DEVELOPMENTS 182
20.12 OASIS MEDICAL 183
20.12.1 COMPANY SNAPSHOT 183
20.12.2 PRODUCT PORTFOLIO 183
20.12.3 RECENT DEVELOPMENTS 183
20.13 PRESTIGE CONSUMER HEALTHCARE INC. 184
20.13.1 COMPANY SNAPSHOT 184
20.13.2 REVENUE ANALYSIS 184
20.13.3 PRODUCT PORTFOLIO 185
20.13.4 RECENT DEVELOPMENT 185
20.14 SAGER PHARMA 186
20.14.1 COMPANY SNAPSHOT 186
20.14.2 PRODUCT PORTFOLIO 186
20.14.3 RECENT DEVELOPMENTS 186
20.15 SIMILASAN CORPORATION 187
20.15.1 COMPANY SNAPSHOT 187
20.15.2 PRODUCT PORTFOLIO 187
20.15.3 RECENT DEVELOPMENTS 187
20.16 SPECTRA VISION CARE 188
20.16.1 COMPANY SNAPSHOT 188
20.16.2 PRODUCT PORTFOLIO 188
20.16.3 RECENT DEVELOPMENTS 188
20.17 SYLENTIS 189
20.17.1 COMPANY SNAPSHOT 189
20.17.2 PRODUCT PORTFOLIO 189
20.17.3 RECENT DEVELOPMENT 189
20.18 THA LABORATORIES 190
20.18.1 COMPANY SNAPSHOT 190
20.18.2 PRODUCT PORTFOLIO 190
20.18.3 RECENT DEVELOPMENTS 190
20.19 WELLONA PHARMA 191
20.19.1 COMPANY SNAPSHOT 191
20.19.2 PRODUCT PORTFOLIO 191
20.19.3 RECENT DEVELOPMENTS 191
20.20 ZYDUS GROUP 192
20.20.1 COMPANY SNAPSHOT 192
20.20.2 REVENUE ANALYSIS 192
20.20.3 PRODUCT PORTFOLIO 193
20.20.4 RECENT DEVELOPMENTS 193
21 QUESTIONNAIRE 194
22 RELATED REPORTS 197
Segmentation
Short Description
Middle East and Africa Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait and Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing". The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance. UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could be due to a higher rate of UV exposure.
It can cause redness, inflammation, and a change in the look of the eye; it can create astigmatism, which can cause blurry vision; and it can cause a whitish or pinkish growth covering the front of the eye. It could affect one or both eyes.
Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.
Market Segmentation:
The Middle East and Africa pterygium drug market is categorized into eight segments: disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel.
On the basis of disease type, the Middle East and Africa pterygium drug market is segmented into progressive pterygium and atrophic pterygium
On the basis of stages, the Middle East and Africa pterygium drug market is segmented into stage 2, stage 3, stage 1, and stage 4
On the basis of treatment, the Middle East and Africa pterygium drug market is segmented into artificial tears/topical lubricants and steroid eye drops
On the basis of formulation, the Middle East and Africa pterygium drug market is segmented into eye drops, eye ointments, and others
On the basis of mode of purchase, the Middle East and Africa pterygium drug market is segmented into prescription and over-the-counter (OTC)
On the basis of population type, the Middle East and Africa pterygium drug market is segmented into geriatric and adults
On the basis of end-user, the Middle East and Africa pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others
On the basis of distribution channel, the Middle East and Africa pterygium drug market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others
Market Players
Some of the major players operating in the Middle East and Africa pterygium drug market are:
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Spectra Vision Care
Bayer AG
Zydus Group
Alcon
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.